Use your browser's back button to choose another title or click here for a New Search.



How to Get the Product

 Brochure (rev 2009) (pdf)

View by section (ATTC)

 

Bookmark and Share

Short Term Opioid Withdrawal Using Buprenorphine (Blending Team Product)

Produced by a NIDA/SAMHSA-ATTC Blending Team, Thomas Freese, Chair. Released in 2006.

Blending Team members: Thomas E. Freese, PhD (Pacific Southwest ATTC), Gregory S. Brigham, PhD (Maryhaven, Inc., OV Node), Beth Finnerty, MPH (Pacific Southwest ATTC), Kay Gresham-Morrison (Southeast ATTC), Judith Harrer, PhD (OV Node), Dennis McCarty, PhD (Oregon Health & Science University, OR/HI Node), Susan A. Storti, PhD, RN (ATTC of New England).

In 2002 tablet formulations of buprenorphine were approved by the FDA for the treatment of opiate addiction. The National Drug Abuse Treatment Clinical Trials Network (CTN) has implemented and completed two clinical trials comparing a short-term opioid withdrawal using buprenorphine versus clonidine in both inpatient and outpatient settings (protocols NIDA-CTN-0001 and NIDA-CTN-0002). The results of these trials suggest that buprenorphine is substantially better than clonidine for opioid detoxification.

In order to prepare the field to effectively integrate this treatment method into their current practice, NIDA formed a Blending Team to develop this package of training materials to instruct providers on how to implement the procedures evaluated through these research protocols. This training was designed to provide a broad overview of the medication, its effects, and the role of non-physician practitioners in providing and supporting the treatment of individuals receiving this medication.

The training package includes PowerPoint training slides, a Trainer's Manual, and a marketing brochure. The training manual is designed to support a half-day face-to-face training to review the results from the CTN research protocols. It then provides instruction for implanting these protocols into treatment settings including methods of evaluation and induction, the taper schedule, and the use of ancillary medications during treatment. Adaptation of these materials to meet the needs of the specific target audience is expected and supported by the materials themselves (for example, detailed speaker notes, not a word-for-word script, are provided for maximum flexibility). The training requires approximately four hours, and trainers should plan to have a laptop, LCD projector, and flip chart paper or easel/white board on hand for the training. (Blending Team Product, English, 2006)

Keywords: Blending Team Products | Blending Team Product: Bup Detox | Buprenorphine | Clinician information | Dissemination | Opioid dependence | Opioid detoxification | Pharmacological therapy | Subutex | Training

Document No: 94

Submitted by CTN Dissemination Librarians (2/27/2006).

AUTHORS SEARCH LINK
Brigham, Gregory S. search mail
Finnerty, Beth search
Freese, Thomas E search mail
Gresham-Morrison, Kay search
Harrer, Judith search
McCarty, Dennis search mail
Storti, Susan A. search
PROTOCOLS
NIDA-CTN-0001 search www
NIDA-CTN-0002 search www

 

 


dark blue line
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 4/2009 -- http://ctndisseminationlibrary.org/display/94.htm
info@ctndisseminationlibrary.org
dark blue line